The paper focuses on recent achievements in the search for new chemical compounds able to inhibit multidrug resistance (MDR) mechanisms in Gram-positive pathogens. An analysis of the results of the search for new efflux pump inhibitors (EPIs) for Gram-positive bacteria, which have been performed over the last decade, indicates that almost all efforts are focused on the NorA (MFS) efflux pump in S. aureus. Considering the chemical structures of the NorA EPIs that have been identified, it can be observed that the most active agents belong to the families of compounds possessing conjugated double bonds, e.g., chalcones, piperine-like compounds, N-cinnamoylphenalkylamides or citral amide derivatives. Indole-, dihydronaphthyl-, 2-chloro-5-bromo-phenyl- or piperidine moieties seem to be profitable for the EPI properties, as well. These results, together with an increasing knowledge about a variety of efflux pumps that are involved in MDR of Gram-positive pathogens underline that further search for new EPIs should pay more attention to develop MDR efflux protein targets, including SMR, MATE, ABC or other members of the MFS family.
References
[1]
Fournier Dit Chabert, J.; Marquez, B.; Neville, L.; Joucla, L.; Broussous, S.; Bouhours, P.; David, E.; Pellet-Rostaing, S.; Marquet, B.; Moreau, N.; et al. Synthesis and evaluation of new arylbenzo[b]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Bioorg. Med. Chem. 2007, 15, 4482–4497.
Sabatini, S.; Gosetto, F.; Serritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J.P.; Carosati, E.; Villarini, M.; Kaatz, G.W.; et al. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: A promising new class of Staphylococcus aureus NorA efflux pump inhibitors. J. Med. Chem. 2012, 55, 3568–3572, doi:10.1021/jm201446h.
[4]
Ruiz, J. Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 2003, 51, 1109–1117, doi:10.1093/jac/dkg222.
[5]
Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 2003, 67, 593–656, doi:10.1128/MMBR.67.4.593-656.2003.
[6]
Li, X.Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria: An update. Drugs 2009, 69, 1555–1623, doi:10.2165/11317030-000000000-00000.
[7]
Kohler, T.; Pechere, J.C.; Plesiat, P. Bacterial antibiotic efflux systems of medical importance. Cell Mol. Life Sci. 1999, 56, 771–778, doi:10.1007/s000180050024.
[8]
Mahamoud, A.; Chevalier, J.; Alibert-Franco, S.; Kern, W.V.; Pages, J.M. Antibiotic efflux pumps in Gram-negative bacteria: The inhibitor response strategy. J. Antimicrob. Chemother. 2007, 59, 1223–1229, doi:10.1093/jac/dkl493.
[9]
Poole, K.; Lomovskaya, O. Can efflux inhibitors really counter resistance? Drug Discov. Today 2006, 3, 145–152, doi:10.1016/j.ddtec.2006.06.011.
[10]
Michalet, S.; Cartier, G.; David, B.; Mariotte, A.M.; Dijoux-franca, M.G.; Kaatz, G.W.; Stavri, M.; Gibbons, S. N-Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1755–1758, doi:10.1016/j.bmcl.2006.12.059.
[11]
Mahamoud, A.; Chevalier, J.; Davin-Regli, A.; Barbe, J.; Pages, J.M. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates. Curr. Drug Targets 2006, 7, 843–847, doi:10.2174/138945006777709557.
[12]
Pages, J.M.; Amaral, L.; Fanning, S. An original deal for new molecule: Reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria. Curr. Med. Chem. 2011, 18, 2969–2980, doi:10.2174/092986711796150469.
[13]
Pages, J.M.; Amaral, L. Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta 2009, 1794, 826–833, doi:10.1016/j.bbapap.2008.12.011.
[14]
Martins, M.; Dastidar, S.G.; Fanning, S.; Kristiansen, J.E.; Molnar, J.; Pages, J.M.; Schelz, Z.; Spengler, G.; Viveiros, M.; Amaral, L. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: Mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents 2008, 31, 198–208, doi:10.1016/j.ijantimicag.2007.10.025.
[15]
Nikaido, H.; Pages, J.M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 2012, 36, 340–363, doi:10.1111/j.1574-6976.2011.00290.x.
[16]
Bolla, J.M.; Alibert-Franco, S.; Handzlik, J.; Chevalier, J.; Mahamoud, A.; Boyer, G.; Kiec-Kononowicz, K.; Pages, J.M. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett. 2011, 585, 1682–1690, doi:10.1016/j.febslet.2011.04.054.
[17]
Handzlik, J.; Szymanska, E.; Chevalier, J.; Otrebska, E.; Kiec-Kononowicz, K.; Pages, J.M.; Alibert, S. Amine-alkyl derivatives of hydantoin: New tool to combat resistant bacteria. Eur. J. Med. Chem. 2011, 46, 5807–5816, doi:10.1016/j.ejmech.2011.09.032.
[18]
Handzlik, J.; Szymanska, E.; Alibert, S.; Chevalier, J.; Otrebska, E.; Pekala, E.; Pages, J.M.; Kiec-Kononowicz, K. Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin. Bioorg. Med. Chem. 2013, 21, 135–145, doi:10.1016/j.bmc.2012.10.053.
[19]
Pradel, E.; Pages, J.M. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob. Agents Chemother. 2002, 46, 2640–2643, doi:10.1128/AAC.46.8.2640-2643.2002.
[20]
Ghisalberti, D.; Masi, M.; Pages, J.M.; Chevalier, J. Chloramphenicol and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 2005, 328, 1113–1118, doi:10.1016/j.bbrc.2005.01.069.
[21]
Lavigne, J.P.; Sotto, A.; Nicolas-Chanoine, M.H.; Bouziges, N.; Bourg, G.; Davin-Regli, A.; Pages, J.M. Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin. Microbiol. Infect. 2012, 18, 539–545, doi:10.1111/j.1469-0691.2011.03607.x.
[22]
Askoura, M.; Mottawea, W.; Abujamel, T.; Taher, I. Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J. Med. 2011, 6, doi:10.3402/ljm.v6i0.5870.
[23]
Drew, D.; Klepsch, M.M.; Newstead, S.; Flaig, R.; De Gier, J.W.; Iwata, S.; Beis, K. The structure of the efflux pump AcrB in complex with bile acid. Mol. Membr. Biol. 2008, 25, 677–682, doi:10.1080/09687680802552257.
[24]
Sennhauser, G.; Bukowska, M.A.; Briand, C.; Grutter, M.G. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J. Mol. Biol. 2009, 389, 134–145, doi:10.1016/j.jmb.2009.04.001.
[25]
Pages, J.M.; Sandrine, A.F.; Mahamoud, A.; Bolla, J.M.; Davin-Regli, A.; Chevalier, J.; Garnotel, E. Efflux pumps of gram-negative bacteria, a new target for new molecules. Curr. Top. Med. Chem. 2010, 10, 1848–1857, doi:10.2174/156802610793176620.
[26]
Ambrus, J.I.; Kelso, M.J.; Bremner, J.B.; Ball, A.R.; Casadei, G.; Lewis, K. Structure-activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus. Bioorg. Med. Chem. Lett. 2008, 18, 4294–4297, doi:10.1016/j.bmcl.2008.06.093.
[27]
Brincat, J.P.; Carosati, E.; Sabatini, S.; Manfroni, G.; Fravolini, A.; Raygada, J.L.; Patel, D.; Kaatz, G.W.; Cruciani, G. Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. J. Med. Chem. 2011, 54, 354–365, doi:10.1021/jm1011963.
[28]
Holler, J.G.; Slotved, H.C.; Molgaard, P.; Olsen, C.E.; Christensen, S.B. Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles. Bioorg. Med. Chem. 2012, 20, 4514–4521, doi:10.1016/j.bmc.2012.05.025.
Nargotra, A.; Sharma, S.; Koul, J.L.; Sangwan, P.L.; Khan, I.A.; Kumar, A.; Taneja, S.C.; Koul, S. Quantitative structure activity relationship (QSAR) of piperine analogs for bacterial NorA efflux pump inhibitors. Eur. J. Med. Chem. 2009, 44, 4128–4135, doi:10.1016/j.ejmech.2009.05.004.
[34]
Sabatini, S.; Gosetto, F.; Manfroni, G.; Tabarrini, O.; Kaatz, G.W.; Patel, D.; Cecchetti, V. Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J. Med. Chem. 2011, 54, 5722–5736, doi:10.1021/jm200370y.
[35]
Wei, P.; Kaatz, G.W.; Kerns, R.J. Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. Bioorg. Med. Chem. Lett. 2004, 14, 3093–3097, doi:10.1016/j.bmcl.2004.04.018.
[36]
Abulrob, A.N.; Suller, M.T.; Gumbleton, M.; Simons, C.; Russell, A.D. Identification and biological evaluation of grapefruit oil components as potential novel efflux pump modulators in methicillin-resistant Staphylococcus aureus bacterial strains. Phytochemistry 2004, 65, 3021–3027, doi:10.1016/j.phytochem.2004.08.044.
[37]
German, N.; Kaatz, G.W.; Kerns, R.J. Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps. Bioorg. Med. Chem. Lett. 2008, 18, 1368–1373, doi:10.1016/j.bmcl.2008.01.014.
[38]
Okandeji, B.O.; Greenwald, D.M.; Wroten, J.; Sello, J.K. Synthesis and evaluation of inhibitors of bacterial drug efflux pumps of the major facilitator superfamily. Bioorg. Med. Chem. 2011, 19, 7679–7689, doi:10.1016/j.bmc.2011.10.011.
Li, X.Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs 2004, 64, 159–204, doi:10.2165/00003495-200464020-00004.
[41]
Tseng, T.T.; Gratwick, K.S.; Kollman, J.; Park, D.; Nies, D.H.; Goffeau, A.; Saier, M.H., Jr. The RND permease superfamily: An ancient, ubiquitous and diverse family that includes human disease and development proteins. J. Mol. Microbiol. Biotechnol. 1999, 1, 107–125.
[42]
Truong-Bolduc, Q.C.; Dunman, P.M.; Strahilevitz, J.; Projan, S.J.; Hooper, D.C. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J. Bacteriol. 2005, 187, 2395–2405, doi:10.1128/JB.187.7.2395-2405.2005.
[43]
DeMarco, C.E.; Cushing, L.A.; Frempong-Manso, E.; Seo, S.M.; Jaravaza, T.A.; Kaatz, G.W. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2007, 51, 3235–3239, doi:10.1128/AAC.00430-07.
Kaatz, G.W.; McAleese, F.; Seo, S.M. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob. Agents Chemother. 2005, 49, 1857–1864, doi:10.1128/AAC.49.5.1857-1864.2005.
Pozzi, G.; Iannelli, F.; Oggioni, M.R.; Santagati, M.; Stefani, S. Genetic elements carrying macrolide efflux genes in streptococci. Curr. Drug Targets Infect. Disord. 2004, 4, 203–206, doi:10.2174/1568005043340641.
[48]
Reynolds, E.; Ross, J.I.; Cove, J.H. Msr(A) and related macrolide/streptogramin resistance determinants: incomplete transporters? Int. J. Antimicrob. Agents 2003, 22, 228–236, doi:10.1016/S0924-8579(03)00218-8.
[49]
Portillo, A.; Ruiz-Larrea, F.; Zarazaga, M.; Alonso, A.; Martinez, J.L.; Torres, C. Macrolide resistance genes in Enterococcus spp. Antimicrob. Agents Chemother. 2000, 44, 967–971, doi:10.1128/AAC.44.4.967-971.2000.
[50]
Schwarz, S.; Kehrenberg, C.; Doublet, B.; Cloeckaert, A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol. Rev. 2004, 28, 519–542, doi:10.1016/j.femsre.2004.04.001.
[51]
Robertson, G.T.; Doyle, T.B.; Lynch, A.S. Use of an efflux-deficient streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents. Antimicrob. Agents Chemother. 2005, 49, 4781–4783, doi:10.1128/AAC.49.11.4781-4783.2005.
[52]
Yoshida, H.; Bogaki, M.; Nakamura, S.; Ubukata, K.; Konno, M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 1990, 172, 6942–6949.
[53]
Pumbwe, L.; Piddock, L.J. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol. Lett. 2002, 206, 185–189, doi:10.1111/j.1574-6968.2002.tb11007.x.
[54]
Kehrenberg, C.; Schwarz, S. fexA, a novel Staphylococcus lentus gene encoding resistance to florfenicol and chloramphenicol. Antimicrob. Agents Chemother. 2004, 48, 615–618, doi:10.1128/AAC.48.2.615-618.2004.
[55]
Borges-Walmsley, M.I.; McKeegan, K.S.; Walmsley, A.R. Structure and function of efflux pumps that confer resistance to drugs. Biochem. J. 2003, 376, 313–338, doi:10.1042/BJ20020957.
[56]
Borges-Walmsley, M.I.; Walmsley, A.R. The structure and function of drug pumps. Trends Microbiol. 2001, 9, 71–79, doi:10.1016/S0966-842X(00)01920-X.
Poole, K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 2005, 56, 20–51, doi:10.1093/jac/dki171.
[59]
Markham, P.N.; Neyfakh, A.A. Efflux-mediated drug resistance in Gram-positive bacteria. Curr. Opin. Microbiol. 2001, 4, 509–514, doi:10.1016/S1369-5274(00)00243-5.
[60]
Kikukawa, T.; Nara, T.; Araiso, T.; Miyauchi, S.; Kamo, N. Two-component bacterial multidrug transporter, EbrAB: Mutations making each component solely functional. Biochim. Biophys. Acta 2006, 1758, 673–679, doi:10.1016/j.bbamem.2006.04.004.
[61]
Putman, M.; van Veen, H.W.; Konings, W.N. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 2000, 64, 672–693, doi:10.1128/MMBR.64.4.672-693.2000.
[62]
Wasaznik, A.; Grinholc, M.; Bielawski, K.P. Active efflux as the multidrug resistance mechanism. Postepy Hig. Med. Dosw. (Online) 2009, 63, 123–133.
[63]
Omote, H.; Hiasa, M.; Matsumoto, T.; Otsuka, M.; Moriyama, Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol. Sci. 2006, 27, 587–593, doi:10.1016/j.tips.2006.09.001.
Kumar, A.; Schweizer, H.P. Bacterial resistance to antibiotics: Active efflux and reduced uptake. Adv. Drug Deliv. Rev. 2005, 57, 1486–1513, doi:10.1016/j.addr.2005.04.004.
[66]
Lubelski, J.; Konings, W.N.; Driessen, A.J. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol. Mol. Biol. Rev. 2007, 71, 463–476, doi:10.1128/MMBR.00001-07.
[67]
Zgurskaya, H.I.; Nikaido, H. Multidrug resistance mechanisms: Drug efflux across two membranes. Mol. Microbiol. 2000, 37, 219–225, doi:10.1046/j.1365-2958.2000.01926.x.
[68]
Wang, K.; Pei, H.; Huang, B.; Zhu, X.; Zhang, J.; Zhou, B.; Zhu, L.; Zhang, Y.; Zhou, F.F. The Expression of ABC Efflux Pump, Rv1217c-Rv1218c, and Its Association with Multidrug Resistance of Mycobacterium tuberculosis in China. Curr. Microbiol. 2013, 66, 222–226, doi:10.1007/s00284-012-0215-3.
[69]
Zechini, B.; Versace, I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent. Pat. Antiinfect. Drug Discov. 2009, 4, 37–50, doi:10.2174/157489109787236256.
[70]
Holler, J.G.; Christensen, S.B.; Slotved, H.C.; Rasmussen, H.B.; Guzman, A.; Olsen, C.E.; Petersen, B.; Molgaard, P. Novel inhibitory activity of the Staphylococcus aureus NorA efflux pump by a kaempferol rhamnoside isolated from Persea lingue Nees. J. Antimicrob. Chemother. 2012, 67, 1138–1144, doi:10.1093/jac/dks005.
[71]
ClinicalTrials.gov. A service of the US National Institutes of Health. Available online: www.clinicaltrials.gov (accessed on 31 January 2013).
